← FDA DRUG APPROVALS

FDA ANDA · ANDA090946

DASETTA 7/7/7

norethindrone and ethinyl estradiol

Sponsor: NOVAST LABS LTD

APPLICATION
ANDA090946
TYPE
ANDA
ORIGINAL APPROVAL
2011-12-22
LATEST ACTION
2022-04-29
ROUTE
ORAL, ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DASETTA 7/7/7Prescription
ETHINYL ESTRADIOL 0.035MG,0.035MG,0.035MG, NORETHINDRONE 0.5MG,0.75MG,1MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 8 · standardAP
2020-07-06Labeling · Supplement 5 · standardAP
2015-12-22Labeling · Supplement 2 · standardAP
2015-12-22Labeling · Supplement 3 · standardAP
2015-12-22Labeling · Supplement 1AP
2011-12-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →